Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

Publisher： Karger

E-ISSN： 1421-9662|120|2|70-74

ISSN： 0001-5792

Source： Acta Haematologica, Vol.120, Iss.2, 2008-10, pp. : 70-74

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Deferasirox Treatment in a Patient with Myelodysplastic Syndrome Results in a Long-Term Reduction in Transfusion Requirements

By  

Acta Haematologica, Vol. 121, Iss. 1, 2009-03 ,pp. : 19-20

Karger

Access to resources Recommend Favorite

Transfusion Independency and Histological Remission in a Patient with Advanced Primary Myelofibrosis Receiving Iron-Chelation Therapy with Deferasirox

By  

Oncology Research and Treatment, Vol. 39, Iss. 6, 2016-05 ,pp. : 384-387

Karger

Access to resources Recommend Favorite

Loss of Transfusion Dependency Following Deferasirox Treatment of Iron Overload in a Woman with Myelofibrosis and Spherocytosis - a Case Report

By  

Oncology Research and Treatment, Vol. 36, Iss. 4, 2013-03 ,pp. : 205-208

Karger

Access to resources Recommend Favorite

CONIFER - Non-Interventional Study to Evaluate Therapy Monitoring During Deferasirox Treatment of Iron Toxicity in Myelodysplastic Syndrome Patients with Transfusional Iron Overload

By  

Oncology Research and Treatment, Vol. 39, Iss. 7-8, 2016-06 ,pp. : 424-431

Karger

Access to resources Recommend Favorite

Transfusion‐dependent thalassaemic patients with renal Fanconi syndrome due to deferasirox use

By  

NEPHROLOGY, Vol. 20, Iss. 12, 2015-12 ,pp. : 931-935

John Wiley & Sons Inc

Access to resources Recommend Favorite